Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15348864 | 0.78 | — | — | |
| SCHEMBL15349216 | 0.77 | MAPT (0.30) | MAPTHPGD | |
| SCHEMBL17398641 | 0.74 | MAPT (0.30) | MAPTHPGD | |
| SCHEMBL25070341 | 0.72 | — | — | |
| SCHEMBL860252 | 0.72 | — | — | |
| SCHEMBL22275632 | 0.71 | — | — | |
| SCHEMBL24347990 | 0.70 | MAPT (0.33) | MAPTHPGD | |
| SCHEMBL25307657 | 0.70 | — | — | |
| SCHEMBL15349154 | 0.70 | — | — | |
| SCHEMBL219390 | 0.69 | ADRA1D (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4034534-A1 | POLYHETEROCYCLIC MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | Pfizer Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114728946-A | Polyheterocyclic modulators of STING (stimulator of interferon genes) | 辉瑞公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021059136-A1 | POLYHETEROCYCLIC MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021059136-A1 | POLYHETEROCYCLIC MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20210087180-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2021-03-25 | — | — | US | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | disclosed |
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | disclosed |
| WO-2007056091-A2 | 2-PHENYL-2H-PYRAZ0LE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | MAPT 4588/4885HPGD 1244/4885 |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | P2RX7, P2RX2, P2RX5 | MAPT 3496/4885HPGD 2877/4885 |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | P2RX7, P2RX1, P2RX3 | MAPT 4718/4885HPGD 2132/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | MAPT 3496/4885HPGD 2877/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | MAPT 3341/4885HPGD 2988/4885 |
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | P2RX7, P2RX1, P2RX3 | MAPT 3930/4885HPGD 1364/4885 |
| US-20210087180-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | MAPT 4588/4885HPGD 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.